Raymond Debbane Biography and Net Worth

Raymond Debbane has been a director since August 2007 and became chairman of our board of directors in February 2012. Mr. Debbane is president and chief executive officer of The Invus Group, LLC, which he founded in New York in 1985 as the exclusive investment advisor of Benelux-based Artal Group S.A. Mr. Debbane serves as chairman or director of a number of private companies in which Invus or Artal Group S.A. have invested. He previously served as a director of WW, Inc. from 1999 until May 2023 and of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc. Before founding The Invus Group, Mr. Debbane was a manager in the Paris office of The Boston Consulting Group, Inc., where he did consulting work for a number of major European and international companies. Mr. Debbane holds an M.B.A. from Stanford University, an M.S. in food science and technology from the University of California at Davis, and a B.S in agricultural sciences and agricultural engineering from American University of Beirut.

What is Raymond Debbane's net worth?: The estimated net worth of Raymond Debbane is at least $3.28 million as of February 25th, 2026. Debbane owns 1,906,186 shares of Lexicon Pharmaceuticals stock worth more than $3,278,640 as of March 13th. This net worth estimate does not reflect any other investments that Debbane may own. Learn More about Raymond Debbane's net worth.
How do I contact Raymond Debbane?: The corporate mailing address for Debbane and other Lexicon Pharmaceuticals executives is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. Lexicon Pharmaceuticals can also be reached via phone at (281) 863-3000 and via email at [email protected]. Learn More on Raymond Debbane's contact information.
Has Raymond Debbane been buying or selling shares of Lexicon Pharmaceuticals?: During the last ninety days, Raymond Debbane has bought $369,980.00 in shares of Lexicon Pharmaceuticals stock. Most recently, on Wednesday, February 25th, Raymond Debbane bought 2,000 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $1.49 per share, with a total value of $2,980.00. Following the completion of the transaction, the director now directly owns 1,906,186 shares of the company's stock, valued at $2,840,217.14. Learn More on Raymond Debbane's trading history.
Who are Lexicon Pharmaceuticals' active insiders?: Lexicon Pharmaceuticals' insider roster includes Raymond Debbane (Director), and Wendy McDermott (Senior Vice President, Human Resources). Learn More on Lexicon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Lexicon Pharmaceuticals?: During the last year, Lexicon Pharmaceuticals insiders bought shares 5 times. They purchased a total of 1,790,462 shares worth more than $2,369,980.60. The most recent insider tranaction occured on February, 25th when Director Raymond Debbane bought 2,000 shares worth more than $2,980.00. Insiders at Lexicon Pharmaceuticals own 13.9% of the company. Learn More about insider trades at Lexicon Pharmaceuticals.
Information on this page was last updated on 2/25/2026.

Raymond Debbane Insider Trading History at Lexicon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/25/2026	Buy	2,000	$1.49	$2,980.00	1,906,186
2/23/2026	Buy	100,000	$1.47	$147,000.00	1,904,186
2/20/2026	Buy	100,000	$1.48	$148,000.00	1,804,186
2/19/2026	Buy	50,000	$1.44	$72,000.00	1,704,186
10/12/2023	Buy	148,820	$1.03	$153,284.60	1,340,847
10/10/2023	Buy	508,306	$1.14	$579,468.84	849,153

Raymond Debbane Buying and Selling Activity at Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Company Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Today's Range

Now: $1.72

$1.66

$1.72

50 Day Range

MA: $1.41

$1.14

$1.76

2 Week Range

Now: $1.72

$0.32

$1.83

Volume

1,925,908 shs

Average Volume

2,455,838 shs

Market Capitalization

$728.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94